Surrozen, Inc. (SRZN)
Surrozen, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Surrozen, Inc. (SRZN) is a Biotechnology company based in US with a market capitalization of $171.9M. Free cash flow was negative at -$30.4M. This page tracks SRZN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 40 employees · IPO Jan 11, 2021
Valuation
Valuation & price
$28.15as of May 17, 2026· -17.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$171.9M
Market cap
—
Revenue growth (YoY)
84.6%
Gross margin
-$30.4M
Free cash flow (USD)
-$82.6M
Net debt
Net cash position
155.0%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Surrozen, Inc.'s market cap?
Surrozen, Inc. (SRZN) has a market capitalization of $171.9M.
What is SRZN's P/E ratio?
A meaningful P/E ratio is not available for SRZN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying SRZN stock?
SEC Form 4 filings show no open-market insider buys at Surrozen, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.